Intellia Therapeutics Inc (NASDAQ:NTLA)
| 11.96 Delayed Data As of Apr 03 |  +0.06 / +0.50%Today’s Change | 9.18 Today|||52-Week Range 19.00 | -18.47% Year-to-Date |
Latest NTLA News | Press Releases
| Is CRISPR Therapeutics Stock a Buy? 8:07am / MotleyFool.com - Paid Partner Content |
Today’s Trading
| Previous close | 11.90 |
| Today’s open | 11.86 |
| Day’s range | 11.56 - 12.10 |
| Volume | 29,451 |
| Average volume (3 months) | 718,236 |
| Market cap | $598.5M |
Data as of 4:00pm ET, 04/03/2020
Growth & Valuation
| Earnings growth (last year) | -6.31% |
| Earnings growth (this year) | -20.39% |
| Earnings growth (next 5 years) | -- |
| Revenue growth (last year) | +41.63% |
| P/E ratio | NM |
| Price/Sales | 16.08 |
| Price/Book | 2.20 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| TLRYTilray Inc | -0.60 | -9.84% |
| CARACara Therapeutics In... | +0.09 | +0.71% |
| IMGNImmunoGen Inc | -0.05 | -1.44% |
| KDMNKadmon Holdings Inc | -0.16 | -4.15% |
Data as of 4:01pm ET, 04/03/2020
Financials
| Next reporting date | May 5, 2020 |
| EPS forecast (this quarter) | -$0.45 |
| Annual revenue (last year) | $43.1M |
| Annual profit (last year) | -$99.5M |
| Net profit margin | -230.92% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters Cambridge, Massachusetts |
Forecasts
